FIORENTINI, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 6.278
AS - Asia 2.994
EU - Europa 2.876
SA - Sud America 588
AF - Africa 78
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
Totale 12.826
Nazione #
US - Stati Uniti d'America 6.174
SG - Singapore 1.033
CN - Cina 1.031
IT - Italia 571
UA - Ucraina 530
BR - Brasile 487
PL - Polonia 396
DE - Germania 335
HK - Hong Kong 284
FI - Finlandia 251
FR - Francia 242
VN - Vietnam 224
GB - Regno Unito 165
IN - India 116
RU - Federazione Russa 106
TR - Turchia 99
IE - Irlanda 98
CA - Canada 46
BD - Bangladesh 43
AR - Argentina 39
MX - Messico 35
BE - Belgio 32
ZA - Sudafrica 29
IQ - Iraq 28
SE - Svezia 28
CZ - Repubblica Ceca 25
ID - Indonesia 21
LU - Lussemburgo 20
EC - Ecuador 18
JP - Giappone 18
NL - Olanda 18
IR - Iran 15
ES - Italia 14
PK - Pakistan 14
NG - Nigeria 12
UZ - Uzbekistan 10
VE - Venezuela 10
AT - Austria 9
MA - Marocco 9
EG - Egitto 8
JO - Giordania 8
PE - Perù 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
CO - Colombia 6
EU - Europa 6
PA - Panama 6
AU - Australia 5
KE - Kenya 5
KR - Corea 5
SA - Arabia Saudita 5
TN - Tunisia 5
BO - Bolivia 4
JM - Giamaica 4
KG - Kirghizistan 4
LT - Lituania 4
PS - Palestinian Territory 4
PY - Paraguay 4
AL - Albania 3
BG - Bulgaria 3
CH - Svizzera 3
CR - Costa Rica 3
ET - Etiopia 3
HU - Ungheria 3
IL - Israele 3
OM - Oman 3
PH - Filippine 3
PT - Portogallo 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AZ - Azerbaigian 2
CY - Cipro 2
DZ - Algeria 2
GR - Grecia 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
NP - Nepal 2
TJ - Tagikistan 2
AO - Angola 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
MN - Mongolia 1
MQ - Martinica 1
NO - Norvegia 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TO - Tonga 1
Totale 12.823
Città #
Singapore 572
Fairfield 556
Ashburn 510
Woodbridge 487
Jacksonville 393
Warsaw 392
Houston 330
Hong Kong 282
Chandler 274
Brescia 254
The Dalles 216
Cambridge 212
San Jose 205
Seattle 205
Beijing 199
Ann Arbor 196
Wilmington 192
Princeton 182
New York 178
Los Angeles 159
Helsinki 147
Nanjing 134
Chicago 133
Dublin 98
Lauterbourg 95
Buffalo 83
Istanbul 77
Dallas 73
Ho Chi Minh City 73
Dearborn 70
Munich 70
Milan 49
Salt Lake City 49
Nanchang 48
Shanghai 48
Moscow 44
Hanoi 43
Des Moines 42
Council Bluffs 41
Hebei 39
Shenyang 39
São Paulo 39
Tianjin 38
Santa Clara 36
San Diego 33
Elk Grove Village 31
London 31
Jinan 30
Lancaster 29
San Francisco 29
Brussels 28
Changsha 27
Pune 27
Redondo Beach 26
Orem 25
Turku 24
Jiaxing 23
Tampa 23
San Mateo 22
Secaucus 22
Poplar 21
Dong Ket 20
Brooklyn 19
Denver 19
Frankfurt am Main 19
Kunming 19
Johannesburg 18
Toronto 18
Hangzhou 17
San Donà Di Piave 17
Tokyo 17
Guangzhou 16
Mexico City 16
Phoenix 15
Brno 14
Rio de Janeiro 14
Ardabil 13
Dudelange 13
Leawood 13
Sterling 13
Verona 13
Lappeenranta 12
Montreal 12
Abuja 11
Belo Horizonte 11
Brasília 11
Jakarta 11
Manchester 11
Miami 11
Ningbo 11
Rome 11
Chennai 10
Da Nang 10
Atlanta 9
Augusta 9
Boston 9
Charlotte 9
Haiphong 9
Kocaeli 9
Amman 8
Totale 8.570
Nome #
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 596
Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus 341
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 296
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 246
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 227
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 226
Immunotherapy failure in adrenocortical cancer: where next? 223
Social networks and health status in the elderly: the ‘ANZIANI IN-RETE’ population-based study 209
Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons 207
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 200
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 193
The D3 dopamine receptor: From structural interactions to function. 189
Palbociclib inhibits proliferation of human adrenocortical tumor cells 189
Kainate Receptor RNA Editing is Markedly Altered by Acute Spinal Cord Injury. 182
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in L-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease 175
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease 175
Receptor Heteromers in Parkinson's Disease and L-DOPA-Induced Dyskinesia 168
Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity 162
Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization. 161
The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons 161
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 153
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 153
Exploring pre-degenerative alterations in humans using induced pluripotent stem cell-derived dopaminergic neurons 150
Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons 148
Ormoni Anteroipofisari 147
Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells 145
Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function 143
A direct interaction between dopamine D1 receptor and phosphatase Shp-2 triggers Erk activation in striatal neurons 140
Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. 139
Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression 136
The NMDA/D1 receptor complex as a new target in drug development 135
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. 134
CaMKII-dependent phosphorylation regulates SAP97/NR2A interaction 130
Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization 130
Dopamine D3 receptors are critically involved in the neurotrophic effects of cocaine and nicotine on the mouse mesencephalic dopaminergic neurons 130
Dopamine D3 receptor heteromerization: Implications for neuroplasticity and neuroprotection 130
The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons. 129
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas 128
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 128
The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes 127
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 127
Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor 126
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine 126
In-vivo silencing of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease 125
Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-kB. 124
Down-regulation of the D1R/Shp-2/Erk1/2 pathway ameliorates L-DOPA-induced dyskinesia in the 6-Hydroxy-Dopamine rat model of Parkinson's disease. 122
D1 receptor properties are modulated by its oligomerization with NMDA receptors 120
Eterodimerizzazione tra recettori dopaminergici D1 e D3: implicazioni funzionali e farmacologiche 117
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 117
Knock-down of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of parkinson's disease. 114
Dopamine D1R activation triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 113
D1 and D3 dopamine receptors form heterooligomers and cointernalization after paired activation of both receptors 112
Neurotrophic effects of cocaine on mouse mesencephalic dopaminergic neurons are mediated by dopamine D3 receptors 112
Role of dopamine D1 receptor and phosphatase Shp-2 in L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. 112
Dopamine-induced Erk activation in striatal neurons is mediated by a direct interaction between the D1 receptor and the tyrosine phosphatase Shp-2. 111
D1 receptor signalling in basal ganglia function and dysfunctions. 111
Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract 109
The Shp-2 tyrosine phosphatase interacts with the dopamine D1 receptor and triggers D1-mediated Erk signalling in striatal neurons. 109
Dopamine D1R activation modulates intracellular signalling and triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 109
Molecular mechanisms underlying dopamine D1R-dependent activation of striatal Erk1/2 in L-DOPA induced dyskinesia in a rat model of Parkinson’s disease. 109
Phenotype changes of prolactinomas 108
Dopamine agonists produce neurotrophic effects on mesencephalic dopaminergic neurons via dopamine D3 receptor activation 108
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of the receptor signalling 108
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation 106
miR-9-5p is involved in the rescue of stress-dependent dendritic shortening of hippocampal pyramidal neurons induced by acute antidepressant treatment with ketamine 104
17-β-estradiol potentiates the neurotrophic and neuroprotective effects mediated by the dopamine D3/acetylcholine nicotinic receptor heteromer in dopaminergic neurons 102
Functional implications of dopamine D1 and D3 receptor heterodimerization 102
Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications 99
Interactions of Dopamine D1 receptors with D3 receptors and glutamate NMDA receptors 97
Downregulation of dopamine D1/ glutamate NMDA receptor complexes in L-DOPA-induced dyskinesia in the rat 95
In-vitro Approaches to Investigate the Detrimental Effect of Light on Dopaminergic Neurons 95
Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine 93
Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway 93
Regulation of D1 receptor signalling by direct interaction with the protein tyrosine phosphatase SHP-2 90
Dendritic remodeling of hippocampal pyramidal neurons, induced by chronic stress and fast-acting antidepressant ketamine, involves miR-9-5p 90
Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor–Receptor Interaction and Striatal Function 89
Frailty and cognitive impairment in elderly patients: miRNAs as new biomarkers (MATCH-In project) 89
Loss of Synaptic D1 Dopamine/N-Methyl-D-aspartate Glutamate Receptor Complexes in L-DOPA-Induced Dyskinesia in the Rat. 88
Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter. 86
Ormoni anteroipofisari 85
Regulation of G-protein coupled receptor trafficking by receptor-receptor interaction 84
G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2 84
Receptor dimerization and the regulation of neuronal function 83
Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors 82
Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. 82
Identification and characterization of two Nf-kB binding sites in the human dopamine d2 receptor promotor 81
Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate NMDA receptors 80
Farmacologia degli ormoni anteroipofisari 80
Generation of human induced pluripotent stem cell lines derived from three Noonan syndrome patients from a single family carrying the heterozygous PTPN11 c.188 A > G (p.Y63C) mutation 78
Meccanismo molecolari e cellulari nel Morbo di Parkinson 78
Downregulation of dopamine D1/NMDA receptor complexes in the post synaptic densities of dyskinetic rats 75
MicroRNAs in frailty associated cognitive impairment MATCH In. 75
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of receptor trafficking and function 74
Oligomerization with NMDA receptor as a novel regulatory mechanism of D1 receptor function 74
Oligomerization of dopamine D1 and glutamate NMDA receptors: a new mechanism regulating striatal function” 73
microRNAs as possible biomarkers of frailty and cognitive impairment: the MATCH-In project 73
Growth factors in pituitary tumors 71
microRNAs as new biomarkers in frailty associated with cognitive impairment in elderly patients (MATCH-In project) 70
The Potential Role of miRNAs in Cognitive Frailty 60
Functional impact of CYFIP2 RNA Editing on actin regulation, axon growth, and spinogenesis 59
Totale 13.049
Categoria #
all - tutte 57.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.445


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021245 0 0 0 0 0 0 0 0 0 0 195 50
2021/2022861 61 130 49 24 6 15 91 42 42 103 70 228
2022/2023771 115 9 18 59 70 225 3 78 122 18 23 31
2023/2024758 56 10 69 73 34 173 27 24 137 27 20 108
2024/20252.143 15 20 9 210 170 182 133 56 169 342 608 229
2025/20263.541 311 463 300 550 363 258 528 178 231 287 72 0
Totale 13.183